marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-13-2024
Lexicon Pharmaceuticals Balance Sheet 2011-2024 | LXRX
Annual Balance Sheet Lexicon Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
78.3 M | 3.52 M | - | -114 M | 209 M | 165 M | 184 M | 54.8 M | -97.2 M | -29.6 M | -15.6 M | -6.97 M | -161 M |
Long Term Debt |
99.5 M | 48.6 M | - | 11.6 M | 234 M | 244 M | 232 M | 85.2 M | 104 M | 87.5 M | 20.2 M | 21.9 M | 23.5 M |
Long Term Debt Current |
1.29 M | 1.29 M | 1.09 M | 553 K | 11 M | 1.12 M | 14.1 M | 16.3 M | 2.02 M | 20.2 M | 1.71 M | 1.57 M | 1.44 M |
Total Non Current Liabilities |
- | - | - | - | 235 M | 274 M | 260 M | 154 M | 246 M | 142 M | 84.7 M | 86.8 M | 112 M |
Total Current Liabilities |
31.5 M | 23.2 M | 22.1 M | 46.8 M | 65.3 M | 36.8 M | 124 M | 165 M | 123 M | 45 M | 19.3 M | 18.3 M | 21.4 M |
Total Liabilities |
136 M | 77.2 M | 23.3 M | 47.4 M | 301 M | 311 M | 384 M | 318 M | 369 M | 187 M | 104 M | 105 M | 133 M |
Deferred Revenue |
- | - | - | - | - | 3.4 M | 40.1 M | 63.4 M | 76.5 M | 1.62 M | 195 K | 128 K | 119 K |
Retained Earnings |
-1.77 B | -1.59 B | -1.49 B | -1.4 B | -1.34 B | -1.47 B | -1.38 B | -1.25 B | -1.11 B | -1.1 B | -1 B | -900 M | -790 M |
Total Assets |
229 M | 194 M | 137 M | 204 M | 418 M | 284 M | 437 M | 476 M | 655 M | 471 M | 274 M | 372 M | 431 M |
Cash and Cash Equivalents |
22.5 M | 46.3 M | 64.1 M | 126 M | 36.1 M | 80.4 M | 61.7 M | 46.6 M | 203 M | 137 M | 37.5 M | 30.4 M | 186 M |
Book Value |
93.1 M | 117 M | 114 M | 156 M | 117 M | -26.4 M | 52.1 M | 157 M | 286 M | 284 M | 170 M | 267 M | 298 M |
Total Shareholders Equity |
93.1 M | 117 M | 114 M | 156 M | 117 M | -26.4 M | 68.3 M | 168 M | 286 M | 284 M | 170 M | 267 M | 298 M |
All numbers in USD currency
Quarterly Balance Sheet Lexicon Pharmaceuticals
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
99.9 M | 99.5 M | 99.9 M | 99.3 M | 98.8 M | 48.8 M | 48.6 M | 23.8 M | - | 23.5 M | - | 1.48 M | 1.62 M | 1.72 M | - | 11.6 M | 235 M | 234 M | 234 M | 234 M | 244 M | 234 M | 244 M | 244 M | 244 M | 244 M | 232 M | 232 M | 232 M | 232 M | 85.2 M | 85.2 M | 85.2 M | 85.2 M | 101 M | 101 M | 101 M | 101 M | 87.5 M | 87.5 M | 87.5 M | 87.5 M | 20.2 M | 20.2 M | 20.2 M | 20.2 M | 21.9 M | 21.9 M | 21.9 M | 21.9 M | 23.5 M | 23.5 M | 23.5 M | 23.5 M |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
143 M | 133 M | 128 M | 137 M | 130 M | 74.7 M | 77.2 M | 47.7 M | - | 43.5 M | 23.3 M | 35.7 M | 34.4 M | 40.7 M | 47.4 M | 47.4 M | 47.4 M | 47.4 M | 301 M | 301 M | 298 M | 301 M | 311 M | 311 M | 311 M | 311 M | 368 M | 384 M | 384 M | 384 M | 318 M | 318 M | 318 M | 318 M | 366 M | 366 M | 366 M | 366 M | 187 M | 187 M | 187 M | 187 M | 104 M | 104 M | 104 M | 104 M | 105 M | 105 M | 105 M | 105 M | 133 M | 133 M | 133 M | 133 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.12 M | 2.24 M | 2.43 M | 2.34 M | 3.4 M | 3.4 M | 3.4 M | 40.4 M | 40.1 M | 40.1 M | 40.1 M | 63.4 M | 63.4 M | 63.4 M | 63.4 M | 76.5 M | 76.5 M | 76.5 M | 76.5 M | 1.62 M | 1.62 M | 1.62 M | 1.62 M | 195 K | 195 K | 195 K | 195 K | 128 K | 128 K | 128 K | 128 K | 119 K | 119 K | 119 K | 119 K |
Retained Earnings |
-1.93 B | -1.87 B | -1.82 B | -1.72 B | -1.67 B | -1.62 B | -1.59 B | -1.56 B | - | -1.51 B | -1.49 B | -1.46 B | -1.44 B | -1.42 B | -1.4 B | -1.4 B | -1.4 B | -1.4 B | -1.34 B | -1.34 B | -1.52 B | -1.34 B | -1.47 B | -1.47 B | -1.47 B | -1.47 B | -1.37 B | -1.38 B | -1.38 B | -1.38 B | -1.25 B | -1.25 B | -1.25 B | -1.25 B | -1.11 B | -1.11 B | -1.11 B | -1.11 B | -1.1 B | -1.1 B | -1.1 B | -1.1 B | -1 B | -1 B | -1 B | -1 B | -900 M | -900 M | -900 M | -900 M | -790 M | -790 M | -790 M | -790 M |
Total Assets |
321 M | 373 M | 417 M | 276 M | 317 M | 163 M | 194 M | 192 M | - | 136 M | 137 M | 172 M | 172 M | 193 M | 204 M | 204 M | 204 M | 204 M | 418 M | 418 M | 233 M | 418 M | 284 M | 284 M | 284 M | 284 M | 437 M | 437 M | 437 M | 437 M | 476 M | 476 M | 476 M | 476 M | 652 M | 652 M | 652 M | 652 M | 471 M | 471 M | 471 M | 471 M | 274 M | 274 M | 274 M | 274 M | 372 M | 372 M | 372 M | 372 M | 431 M | 431 M | 431 M | 431 M |
Cash and Cash Equivalents |
34.6 M | 35.6 M | 96.5 M | 21.1 M | 102 M | 26 M | 46.3 M | 18.8 M | 21.4 M | 59.5 M | 64.1 M | 92.1 M | 89.9 M | 97.7 M | 126 M | 126 M | 126 M | 126 M | 36.1 M | 36.1 M | 11.1 M | 36.1 M | 80.4 M | 80.4 M | 80.4 M | 80.4 M | 61.7 M | 61.7 M | 61.7 M | 61.7 M | 46.6 M | 46.6 M | 46.6 M | 46.6 M | 203 M | 203 M | 203 M | 203 M | 137 M | 137 M | 137 M | 137 M | 37.5 M | 37.5 M | 37.5 M | 37.5 M | 30.4 M | 30.4 M | 30.4 M | 30.4 M | 186 M | 186 M | 186 M | 186 M |
Book Value |
179 M | 240 M | 289 M | 140 M | 186 M | 88 M | 117 M | 144 M | - | 92.7 M | 114 M | 137 M | 137 M | 153 M | 156 M | 156 M | 156 M | 156 M | 117 M | 117 M | -64.9 M | 117 M | -26.4 M | -26.4 M | -26.4 M | -26.4 M | 68.3 M | 52.1 M | 52.1 M | 52.1 M | 157 M | 157 M | 157 M | 157 M | 286 M | 286 M | 286 M | 286 M | 284 M | 284 M | 284 M | 284 M | 170 M | 170 M | 170 M | 170 M | 267 M | 267 M | 267 M | 267 M | 298 M | 298 M | 298 M | 298 M |
Total Shareholders Equity |
179 M | 240 M | 289 M | 140 M | 186 M | 88 M | 117 M | 144 M | 70.8 M | 92.7 M | 114 M | 137 M | 137 M | 153 M | 156 M | 156 M | 156 M | 156 M | 117 M | 117 M | -64.9 M | 117 M | -26.4 M | -26.4 M | -26.4 M | -26.4 M | 68.3 M | 52.1 M | 52.1 M | 52.1 M | 168 M | 157 M | 157 M | 157 M | 286 M | 286 M | 286 M | 286 M | 284 M | 284 M | 284 M | 284 M | 170 M | 170 M | 170 M | 170 M | 267 M | 267 M | 267 M | 267 M | 298 M | 298 M | 298 M | 298 M |
All numbers in USD currency